Illumina, Inc.

ILMN · Nasdaq · ·

Karşılaştır

$209,61-%1,512 Kas kapanış

27 Eylül 2026 tarihine kadarki rakamlar, 30 Ekim 2026 tarihinde sunulan 10-Q raporundan

1W: -%1,7
1M: -%22,7

Illumina, Inc. (ILMN) hisse senedi — iyi bir şirket mi? — InspectStocks

Illumina, Inc.

ILMN · Nasdaq · ·

Karşılaştır

$209,61-%1,512 Kas kapanış

27 Eylül 2026 tarihine kadarki rakamlar, 30 Ekim 2026 tarihinde sunulan 10-Q raporundan

1W: -%1,7
1M: -%22,7

Just reported

Q3 FY2027 results

From Illumina's results release of 29 Ekim 2026; its quarterly report has since been filed.

Revenue
Actual
$1,13B
+%4,2 y/y
-%2,6 q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1,43
+%46 y/y
+%5,9 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$305M
+%34 y/y
+%24 q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

The full earnings report →

Keep exploring

The themes Illumina is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Seçki
Lab tools & diagnostics
InspectStocks tarafından · 20 companies
Instruments, supplies and testing services for labs, drugmakers and doctors.
Fiyat, 1 yıl
+%21,6
Gelir, 1 yıl
+%7,8
+14
A 8B 8C 2D 1F 1

Highest-graded in Diagnostics and Research

Graded A or B and worth $2B or more: A first, then the largest.

All 42 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Nasıl para kazanıyor

Sequencing consumables%73
Services and other%16
Sequencing instruments%11

Gelir payları quarter ended 2026-03-31 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.

Rekabet ettiği şirketler

Ne satıyor6

NovaSeq X
A high-throughput DNA-sequencing machine used by customers that need to process large numbers of samples.
MiSeq i100
A lower-throughput DNA-sequencing machine for labs running smaller or more project-based batches.
NovaSeq 6000
A high-throughput DNA-sequencing machine that some customers continue to use alongside newer systems.

3 tane daha göster

StrataMap Spatial
A sequencing-based workflow that helps researchers study biological activity in specific locations within tissue.
SomaScan and SomaSeq
Tools for measuring proteins and connecting protein measurements with genetic information.
Billion Cell Atlas
A large collection of data on how cells respond to genetic changes, sold to drug companies for biological research and drug discovery.

Kim alıyor3

Clinical laboratories and hospitals buy sequencing machines and supplies for testing, including cancer, inherited-disease and screening applications.
Universities and research laboratories buy sequencing equipment and supplies to study genes, cells and biological processes.
Drug companies buy sequencing-related services and biological data to support research and drug discovery.

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

1Repeat consumables purchases depend on customers using Illumina machines and running samples on them.
2Clinical sequencing demand and purchases by large clinical customers are important sources of business growth.
3Instrument production depends on access to memory and other critical components, while freight costs affect expenses.
4Business in China is affected by restrictions associated with China's unreliable entity list.

Ters gidebilecekler

1If clinical laboratories expand sequencing use more slowly or run fewer samples, demand for sequencing supplies could fall.
2Uncertain research funding can reduce purchases by universities and research customers; research and applied consumables were declining in the quarter discussed on the call.
3Higher memory and freight costs, or difficulty obtaining critical components, can increase costs and disrupt instrument supply.

Tüm finansal tablolar →

Illumina, Inc. hakkında

Illumina makes machines that read DNA and sells the chemicals and other supplies customers use to run samples on them. Hospitals and clinical laboratories use sequencing for applications such as cancer testing, inherited-disease testing and screening; researchers and drug companies use it to study biology and develop medicines. Illumina also sells tools for measuring proteins and provides biological data and related services.

Merkez: San Diego, California
Kuruluş: 1998
İşlem gördüğü borsa: Nasdaq
Mali yıl sonu: Sunday nearest December 31

Illumina, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Just reported

Q3 FY2027 results

From Illumina's results release of 29 Ekim 2026; its quarterly report has since been filed.

Revenue
Actual
$1,13B
+%4,2 y/y
-%2,6 q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1,43
+%46 y/y
+%5,9 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$305M
+%34 y/y
+%24 q/q
Guided
—
No guide given

The full earnings report →